NEVRO CORP.
NVRO
NVRO was delisted on the 2nd of April, 2025.
207 hedge funds and large institutions have $6.36B invested in NEVRO CORP. in 2021 Q2 according to their latest regulatory filings, with 38 funds opening new positions, 75 increasing their positions, 64 reducing their positions, and 35 closing their positions.
21% more capital invested
Capital invested by funds: $5.24B → $6.36B (+$1.12B)
17% more repeat investments, than reductions
Existing positions increased: 75 | Existing positions reduced: 64
14% more call options, than puts
Call options by funds: $34.8M | Put options by funds: $30.5M
1% more funds holding
Funds holding: 204 → 207 (+3)
9% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 35
Top Buyers
| 1 |
HM
HealthCor Management
New York
|
+$58.7M |
| 2 |
JSP
Jackson Square Partners
Larkspur,
California
|
+$45.8M |
| 3 |
FAM
Fred Alger Management
New York
|
+$44.9M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$43.9M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$38.4M |
Top Sellers
| 1 |
Citadel Advisors
Miami,
Florida
|
-$43.3M |
| 2 |
Morgan Stanley
New York
|
-$37.2M |
| 3 |
Goldman Sachs
New York
|
-$36.5M |
| 4 |
Norges Bank
Oslo,
Norway
|
-$28.5M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$26M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
226
Alyeska Investment Group
Chicago,
Illinois
| – | -$510K | -3,655 | Closed |
|
227
HSBC Holdings
London,
United Kingdom
| – | -$411K | -2,923 | Closed |
|
|
QI
228
QS Investors
New York
| – | -$367K | -2,630 | Closed |
|
|
WS
229
Wedbush Securities
Los Angeles,
California
| – | -$348K | -2,495 | Closed |
|
|
BC
230
Bridgefront Capital
Austin,
Texas
| – | -$278K | -1,993 | Closed |
|
231
Federated Hermes
Pittsburgh,
Pennsylvania
| – | -$277K | -1,987 | Closed |
|
|
VF
232
Virtu Financial
New York
| – | -$246K | -1,766 | Closed |
|
233
Verition Fund Management
Greenwich,
Connecticut
| – | -$230K | -1,647 | Closed |
|
|
OC
234
Oppenheimer & Co
New York
| – | -$210K | -1,504 | Closed |
|
|
TI
235
Trexquant Investment
Stamford,
Connecticut
| – | -$207K | -1,486 | Closed |
|
|
PI
236
PEAK6 Investments
Chicago,
Illinois
| – | -$37.3K | -239 | Closed |
|
|
GWM
237
Geneos Wealth Management
Englewood,
Colorado
| – | -$7K | -41 | Closed |
|
|
MWP
238
Meridian Wealth Partners
Exton,
Pennsylvania
| – | -$1K | -6 | Closed |
|
NVRO Hedge Fund Activity: Q2 2021 in Review
207 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in NEVRO CORP. (NVRO) for Q2 2021, worth a combined $6.36B — up 21% from $5.24B a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new NVRO positions and 35 closed out — a net gain of 3 holders — while 75 added to existing stakes and 64 trimmed.
The largest buyer was HealthCor Management, opening a new position worth an estimated $58.7M. The largest seller was Citadel Advisors, exiting entirely with an estimated $43.3M sold.
- 207 institutional investors held NEVRO CORP. (NVRO) as of Q2 2021, up from 204 in Q1 2021.
- Funds reported $6.36B of NEVRO CORP. stock for Q2 2021, up 21% quarter-over-quarter.
- 38 funds opened new NEVRO CORP. positions in Q2 2021 and 35 closed out, a net change of +3 holders.
- The largest NEVRO CORP. buyer in Q2 2021 was HealthCor Management, an estimated $58.7M added.
- The largest NEVRO CORP. seller in Q2 2021 was Citadel Advisors, an estimated $43.3M sold.
Based on aggregated 13F filings for Q2 2021.